The two sides of HER2/neu: immune escape versus surveillance
Author:
Publisher
Elsevier BV
Subject
Molecular Biology,Molecular Medicine
Reference69 articles.
1. Emerging targeted therapies for breast cancer;Alvarez;J. Clin. Oncol.,2010
2. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer;Junttila;Cancer Res.,2010
3. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors;Nielsen;Breast,2013
4. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets;Clynes;Nat. Med.,2000
5. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer;Musolino;J. Clin. Oncol.,2008
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells;Frontiers in Immunology;2023-10-25
2. ERBB2 as a prognostic biomarker correlates with immune infiltrates in papillary thyroid cancer;Frontiers in Genetics;2022-11-09
3. Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies;JNCI: Journal of the National Cancer Institute;2020-12-22
4. HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15;Immunogenetics;2018-08-25
5. Cancer–adipose tissue interaction and fluid flow synergistically modulate cell kinetics, HER2 expression, and trastuzumab efficacy in gastric cancer;Gastric Cancer;2018-04-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3